Date: 2013-10-29
Type of information: Commercialisation agreement
Compound: Adasuve® (Staccato® Loxapine)
Company: AOP Orphan Pharmaceuticals (Austria) Ferrer Internacional (Spain)
Therapeutic area: Mental diseases - CNS diseases
Type agreement: commercialisation
Action mechanism:
Disease:
Details: * On October 29, 2013, AOP Orphan and Ferrer Internacional have announced that they are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe. Adasuve® has been developed to provide rapid treatment for agitation in patients suffering from schizophrenia or manic depression. It combines the patented Staccato system with loxapine, a well-established anti-psychotic. The Staccato system – a hand-held, single-dose inhaler – allows the active agent to reach the lungs very quickly, meaning that it works just as swiftly as an intravenous injection. Consequently, Adasuve® is an easy-to-use and very reliable form of inhalation therapy, which quickly relieves the patient’s agitation.
The Austrian pharmaceutical company AOP Orphan markets Adasuve® in Austria, Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Switzerland, Slovakia and Slovenia. Other regions are currently being discussed.
Financial terms:
Latest news:
